open access

Vol 5, No 1 (2002)
Submitted: 2012-01-23
Published online: 2002-01-17
Get Citation

Alteration of 99mTc-DMSA biodistribution in glomerulonephritis

Milena Rajić, Mamcilo Bogicevic, Slobodan Antic, Branka Mitic, Marina Avramovic, Slobodan Ilic, Marina Vlajkovic, Marina Mitic-Zlatovic, Vladislav Stefanovic
Nucl. Med. Rev 2002;5(1):15-19.

open access

Vol 5, No 1 (2002)
Submitted: 2012-01-23
Published online: 2002-01-17

Abstract

BACKGROUND: The aim of this study was to assess the relation between 99mTc-DMSA biodistribution and its reliability as a marker of renal function in patients with glomerular kidney diseases.
MATERIAL AND METHODS: Sixty-seven patients involved in this study were classified into two groups according to 99mTc-DTPA clearance and serum creatinine values: the 1st group consisted of 42 patients without renal failure while the 2nd group included 25 patients with renal failure. 99mTc-DMSA biodistribution was determined by measuring kidney, blood and urine activity at 2 h and 4 h.
RESULTS: The results, compared with those of 23 healthy volunteers, indicated the quantitative alteration of 99mTc-DMSA distribution in both glomerulonephritis patient groups. In reference to the control mean values of 2 h and 4 h, in patients without renal failure, kidney activity was found decreased to 52% and 57%, while the blood activity increase of 37% and 44% was recorded together with the urine activity increase of 38% and 23%. In patients with renal failure the alterations of renal and blood activity were more remarkable, but the urine loss was found to be unchanged.
CONCLUSIONS: It is suggested that these biodistribution changes originate mainly from tubular impairment. However, in glomerulonephritis patients, altered glomerular filtration might considerably affect biodistribution of this radiopharmaceutical and limits its suitability for precise quantitative estimation of renal function.

Abstract

BACKGROUND: The aim of this study was to assess the relation between 99mTc-DMSA biodistribution and its reliability as a marker of renal function in patients with glomerular kidney diseases.
MATERIAL AND METHODS: Sixty-seven patients involved in this study were classified into two groups according to 99mTc-DTPA clearance and serum creatinine values: the 1st group consisted of 42 patients without renal failure while the 2nd group included 25 patients with renal failure. 99mTc-DMSA biodistribution was determined by measuring kidney, blood and urine activity at 2 h and 4 h.
RESULTS: The results, compared with those of 23 healthy volunteers, indicated the quantitative alteration of 99mTc-DMSA distribution in both glomerulonephritis patient groups. In reference to the control mean values of 2 h and 4 h, in patients without renal failure, kidney activity was found decreased to 52% and 57%, while the blood activity increase of 37% and 44% was recorded together with the urine activity increase of 38% and 23%. In patients with renal failure the alterations of renal and blood activity were more remarkable, but the urine loss was found to be unchanged.
CONCLUSIONS: It is suggested that these biodistribution changes originate mainly from tubular impairment. However, in glomerulonephritis patients, altered glomerular filtration might considerably affect biodistribution of this radiopharmaceutical and limits its suitability for precise quantitative estimation of renal function.
Get Citation

Keywords

99mTc-DMSA; kidney activity; blood activity; urine activity; glomerulonephritis

About this article
Title

Alteration of 99mTc-DMSA biodistribution in glomerulonephritis

Journal

Nuclear Medicine Review

Issue

Vol 5, No 1 (2002)

Pages

15-19

Published online

2002-01-17

Page views

737

Article views/downloads

2018

Bibliographic record

Nucl. Med. Rev 2002;5(1):15-19.

Keywords

99mTc-DMSA
kidney activity
blood activity
urine activity
glomerulonephritis

Authors

Milena Rajić
Mamcilo Bogicevic
Slobodan Antic
Branka Mitic
Marina Avramovic
Slobodan Ilic
Marina Vlajkovic
Marina Mitic-Zlatovic
Vladislav Stefanovic

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

phone: +48 58 320 94 94, fax: +48 58 320 94 60, e-mail: viamedica@viamedica.pl